Skip to content
Screener

Nuvation Bio NUVB Q1 2026 earnings

Reported May 4, 2026 · After market close

Revenue$83.2MBeat by $17.0M
EPS$0.01Miss by $0.11
Revenue estimate$66.2M
EPS estimate$0.12

Next report

Nov 2, 2026 (in a month)
Revenue estimate$35.3M
EPS estimate-$0.12

Financials

Q1 2026

Income statement

See full
Revenue$83.2M+2,599%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.49B+150%
Enterprise value$1.42B+154%
P/S10.4×-44.0×

Profitability

See full
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Segments

By product

See full
License$64.7M+1,999%
Product Revenue$18.5M+2,213%
Royalty Revenue$1.4M+600%
Research And Development Service Revenue$700.0K-63.2%

FAQ

When did Nuvation Bio report Q1 2026 earnings?
Nuvation Bio (NUVB) reported Q1 2026 earnings on May 4, 2026 after market close.
What were Nuvation Bio's Q1 2026 revenue and EPS?
Nuvation Bio reported revenue of $83.2M and eps of $0.01 for Q1 2026.
Did Nuvation Bio beat estimates in Q1 2026?
Revenue beat the consensus estimate of $66.2M by $17.0M. EPS missed the consensus estimate of $0.12 by $0.11.
How did Nuvation Bio's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2598.7% from $3.1M a year earlier.
Where can I find Nuvation Bio's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-204056) and the 10-Q periodic report (0001193125-26-203964) directly on SEC EDGAR. The filing index links above go to sec.gov.